bupivacaine has been researched along with Hallux Valgus in 14 studies
Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
Hallux Valgus: Lateral displacement of the great toe (HALLUX), producing deformity of the first METATARSOPHALANGEAL JOINT with callous, bursa, or BUNION formation over the bony prominence.
Excerpt | Relevance | Reference |
---|---|---|
"5% levobupivacaine (L) and 1% mepivacaine (M) for popliteal block for hallux valgus surgery." | 9.16 | [Comparison of 3 combinations of 0.5% levobupivacaine and 1% mepivacaine in popliteal sciatic block in hallux valgus outpatient surgery]. ( Anglada, MT; Fábregas, N; Faulí, A; Gambús, P; Gomar, C; López, A; Pons, M; Sala, X, 2012) |
"The use of a single dose of either levobupivacaine or ropivacaine to provide anesthesia for a popliteal approach to hallux valgus surgery is effective for controlling postoperative pain." | 9.14 | [Ultrasound-guided single dose injection of 0.5% levobupivacaine or 0.5% ropivacaine for a popliteal fossa nerve block in unilateral hallux valgus surgery]. ( Anglada, MT; Fàbregas, N; Faulí, A; López, A; Pons, M; Pujol, E, 2010) |
"The objective of this study was to review the use of liposomal bupivacaine as a multimodal pain management adjunct following hallux valgus surgery." | 7.80 | Liposomal bupivacaine in hallux valgus surgery: a multimodal pain management adjunct. ( Huh, J; Parekh, SG, 2014) |
"A randomised clinical study was conducted on ambulatory patients subjected to Hallux valgus surgery, assigned into two groups: BNP: peripheral nerve blockage: posterior tibial and the common peroneal with 80mg of lidocaine, 100mg of mepivacaine and 25mg of levobupivacaine." | 5.16 | [Comparison of the post-surgical analgesic effectiveness of tibial (at internal malleolus level) and common peroneal nerve block with infiltration of the surgical wound in Outpatient Surgery of the hallux valgus]. ( Martín, MA; Ollé, G; Pellejero, JA; Pou, N; Torruella, R; Yuste, M, 2012) |
"5% levobupivacaine (L) and 1% mepivacaine (M) for popliteal block for hallux valgus surgery." | 5.16 | [Comparison of 3 combinations of 0.5% levobupivacaine and 1% mepivacaine in popliteal sciatic block in hallux valgus outpatient surgery]. ( Anglada, MT; Fábregas, N; Faulí, A; Gambús, P; Gomar, C; López, A; Pons, M; Sala, X, 2012) |
"The use of a single dose of either levobupivacaine or ropivacaine to provide anesthesia for a popliteal approach to hallux valgus surgery is effective for controlling postoperative pain." | 5.14 | [Ultrasound-guided single dose injection of 0.5% levobupivacaine or 0.5% ropivacaine for a popliteal fossa nerve block in unilateral hallux valgus surgery]. ( Anglada, MT; Fàbregas, N; Faulí, A; López, A; Pons, M; Pujol, E, 2010) |
"To compare intraoperative and postoperative clinical properties of levobupivacaine and ropivacaine for sciatic nerve block, 50 ASA physical status I and II patients undergoing hallux valgus repair received a femoral nerve block with 15 mL of 2% mepivacaine." | 5.10 | A double-blinded, randomized comparison of either 0.5% levobupivacaine or 0.5% ropivacaine for sciatic nerve block. ( Borghi, B; Casati, A; Cerchierini, E; Fanelli, G; Grispigni, C; Santorsola, R; Sassoli, V; Torri, G, 2002) |
"The objective of this study was to review the use of liposomal bupivacaine as a multimodal pain management adjunct following hallux valgus surgery." | 3.80 | Liposomal bupivacaine in hallux valgus surgery: a multimodal pain management adjunct. ( Huh, J; Parekh, SG, 2014) |
"The surgical treatment of hallux valgus deformity is connected with significant postoperative pain." | 2.80 | [Preemptive local anesthetic infiltration in hallux valgus one-day surgery]. ( Gądek, A; Liszka, H, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (7.14) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (42.86) | 29.6817 |
2010's | 7 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Robbins, J | 1 |
Green, CL | 1 |
Parekh, SG | 2 |
Huh, J | 1 |
Gądek, A | 1 |
Liszka, H | 1 |
Taboada, M | 2 |
Rodríguez, J | 2 |
Bermudez, M | 1 |
Valiño, C | 1 |
Ulloa, B | 1 |
Aneiros, F | 1 |
Gude, F | 1 |
Cortés, J | 1 |
Alvarez, J | 2 |
Atanassoff, PG | 1 |
Pujol, E | 1 |
Faulí, A | 2 |
Anglada, MT | 2 |
López, A | 2 |
Pons, M | 2 |
Fàbregas, N | 2 |
Golf, M | 1 |
Daniels, SE | 1 |
Onel, E | 1 |
Martín, MA | 1 |
Ollé, G | 1 |
Pellejero, JA | 1 |
Torruella, R | 1 |
Yuste, M | 1 |
Pou, N | 1 |
Gomar, C | 1 |
Sala, X | 1 |
Gambús, P | 1 |
Sinardi, D | 1 |
Marino, A | 1 |
Chillemi, S | 1 |
Siliotti, R | 1 |
Mondello, E | 1 |
Carceller, J | 1 |
Lagunilla, J | 1 |
Bárcena, M | 1 |
Palmisani, S | 1 |
Arcioni, R | 1 |
Di Benedetto, P | 2 |
De Blasi, RA | 1 |
Mercieri, M | 1 |
Ronconi, P | 1 |
Casati, A | 2 |
Borghi, B | 1 |
Fanelli, G | 1 |
Cerchierini, E | 2 |
Santorsola, R | 2 |
Sassoli, V | 1 |
Grispigni, C | 2 |
Torri, G | 2 |
Chelly, JE | 1 |
Nobili, F | 1 |
Porter, KM | 1 |
Davies, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Impact of Liposomal Bupivicaine on Post-Operative Pain in Orthopaedic Trauma Surgery: A Double-Blind Prospective Randomized Control Trial[NCT02480621] | Phase 3 | 84 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
The Efficacy of Automated Intermittent Boluses for Continuous Femoral Nerve Block: a Prospective, Randomized Comparison to Continuous Infusions[NCT01226927] | 45 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride[NCT03270514] | Phase 3 | 60 participants (Actual) | Interventional | 2018-11-15 | Completed | ||
Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study[NCT03303794] | Phase 3 | 25 participants (Actual) | Interventional | 2017-10-25 | Terminated (stopped due to Interim Analysis showed no significance) | ||
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing First Metatarsal Osteotomy (B[NCT00890682] | Phase 3 | 193 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
Prospective Randomized Trial of Penile Nerve Block With Liposomal Bupivacaine for Hypospadias Repair vs Standard Penile Block With Bupivacaine[NCT04479371] | Phase 1 | 0 participants (Actual) | Interventional | 2021-07-31 | Withdrawn (stopped due to Limited funding and resources to complete FDA requirements for enrollment) | ||
The Use of Liposomal Bupivacaine for Pain Control Following Mastectomy and Breast Reconstruction[NCT03722927] | Phase 4 | 3 participants (Actual) | Interventional | 2018-06-14 | Completed | ||
A Randomized Controlled Trial of Wound Infiltration With Extended-release Versus Short-acting Bupivacaine Before Laparoscopic or Robotic Hysterectomy[NCT02352922] | Phase 4 | 64 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
[NCT00523289] | Phase 4 | 48 participants (Anticipated) | Interventional | 2007-10-31 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
A Visual Analog Scale (VAS) ranging from 0 to 10 in increments of 1 was used to both qualitatively and quantitatively assess the level and severity of pain during the time points ranging from the immediate post-operative period through 72 hours post-operative. Each number on the scale is accompanied by a visual facial expression that indicates the level of pain, discomfort, and distress appropriate to the number on the scale. The more severe the level of pain, the higher the corresponding number and more distressing the accompanying facial expression. A VAS score of 0 indicates no active pain level and is accompanied by a pleasantly smiling face whereas a VAS score of 10 indicates the most severe active pain level and is accompanied by a visibly-distraught face that is frowning, grimacing, and sweating. The combination of facial expressions and numbers is supposed to provide a language-independent, validated means of assessing pain levels. (NCT02480621)
Timeframe: Immediate post-operative period until 72 hours post-operatively
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
4 Hours Post-operative | Post-operative Day 1 | Post-operative Day 2 | Post-operative Day 3 | |
Control | 7.05 | 7.49 | 6.64 | 5.72 |
Liposomal Bupivacaine With Bupivacaine | 4.03 | 6.60 | 5.22 | 4.08 |
Readmission to hospital will be noted (NCT03270514)
Timeframe: From end of surgery assessed up to 30 days post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Exparel Injectable Product | 3 |
Bupivacaine Hydrochloride | 3 |
Mortality will be noted at specific timepoints (NCT03270514)
Timeframe: From end of surgery assessed up to 30 days post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Exparel Injectable Product | 0 |
Bupivacaine Hydrochloride | 1 |
Episodes of NIV such as upper airway masks or similar devices will be quantified (NCT03270514)
Timeframe: From time of end of surgery to 72 hours post-operatively or until hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Exparel Injectable Product | 6 |
Bupivacaine Hydrochloride | 5 |
Patient will give an assessment regarding pain management on a scale of 0 - 10 with 0 indicating the lowest satisfaction with pain management and 10 indicating the highest satisfaction with pain management (NCT03270514)
Timeframe: Given at the time of discharge up to 30 days post-operatively
Intervention | score on a scale (Median) |
---|---|
Exparel Injectable Product | 10 |
Bupivacaine Hydrochloride | 10 |
The time it takes until patient ambulates will be measured (NCT03270514)
Timeframe: From time of end of surgery to time of mobilization up to 72 hours or discharge, *assessed up to 120 hours*
Intervention | hours (Median) |
---|---|
Exparel Injectable Product | 42 |
Bupivacaine Hydrochloride | 45 |
The time it takes until the patient is able to/medically cleared to consume food or liquid will be measured (NCT03270514)
Timeframe: From time of end of surgery to time of oral intake up to 72 hours post-operatively or until hospital discharge
Intervention | hours (Median) |
---|---|
Exparel Injectable Product | 7 |
Bupivacaine Hydrochloride | 5.6 |
The time it takes until the patient advances from bedrest to out of bed (OOB) to chair will be measured (NCT03270514)
Timeframe: From time of end of surgery to time of mobilization up to 72 hours post-operatively
Intervention | hours (Median) |
---|---|
Exparel Injectable Product | 16 |
Bupivacaine Hydrochloride | 16 |
Whether a patient experiences at least one episode of nausea and emesis will be measured (NCT03270514)
Timeframe: From time of end of surgery to 72 hours post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Exparel Injectable Product | 3 |
Bupivacaine Hydrochloride | 9 |
Instances of re-intubation will be recorded (NCT03270514)
Timeframe: From time of end of surgery to patient discharge up to one week
Intervention | Participants (Count of Participants) |
---|---|
Exparel Injectable Product | 3 |
Bupivacaine Hydrochloride | 3 |
The time it takes until the patient is extubated post-operatively will be measured (NCT03270514)
Timeframe: From the end of surgery until the patient is extubated up to 72 hours post-operatively
Intervention | hours (Median) |
---|---|
Exparel Injectable Product | 3.85 |
Bupivacaine Hydrochloride | 3.47 |
Frequency of incentive spirometry will be measured (NCT03270514)
Timeframe: From time of end of surgery to 72 hours post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Exparel Injectable Product | 29 |
Bupivacaine Hydrochloride | 31 |
Length of both hospital and ICU stay will be measured (NCT03270514)
Timeframe: From date of surgery assessed up to 30 day post-operatively
Intervention | days (Median) | |
---|---|---|
Length of ICU stay | Length of postoperative hospital stay | |
Bupivacaine Hydrochloride | 1.71 | 6 |
Exparel Injectable Product | 1.51 | 7 |
Postoperative pain scores evaluated by numeric rating scale or (NRS) where 0- no pain and 10- worst pain, at rest and at movement (NCT03270514)
Timeframe: NRS scores will be evaluated every 4 hours until 24 hours post-operatively, every 8 hours until 48 hours post-operatively, and every 12 hours for 72 hours post-operatively
Intervention | score on a scale (Mean) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4hrs. at rest | 4hrs. with movement | 8hrs. at rest | 8hrs. with movement | 12hrs. at rest | 12hrs. with movement | 16hrs. at rest | 16hrs. with movement | 20hrs. at rest | 20hrs. with movement | 24hrs. at rest | 24hrs. with movement | 32hrs. at rest | 32hrs. with movement | 40hrs. at rest | 40hrs. with movement | 48hrs. at rest | 48hrs. with movement | 60hrs. at rest | 60hrs. with movement | 72hrs. at rest | 72hrs. with movement | |
Bupivacaine Hydrochloride | 5.03 | 6.64 | 4.996 | 6.6 | 4.962 | 6.56 | 4.928 | 6.52 | 4.894 | 6.48 | 4.86 | 6.44 | 4.792 | 6.32 | 4.724 | 6.24 | 4.656 | 6.16 | 4.554 | 6.04 | 4.452 | 5.92 |
Exparel Injectable Product | 4.7482 | 5.75 | 4.7262 | 5.74 | 4.7042 | 5.73 | 4.6822 | 5.72 | 4.6602 | 5.71 | 4.6382 | 5.7 | 4.5942 | 5.68 | 4.5282 | 5.66 | 4.4622 | 5.64 | 4.3742 | 5.61 | 4.2862 | 5.58 |
Stress response suppression as a result of treatment will be evaluated by comparing hormone levels between the groups. Serum cortisol levels will be taken to measure this. (NCT03270514)
Timeframe: Measured 8, 48, and 72 hours post-operatively
Intervention | µg/dL (Median) | ||
---|---|---|---|
8 hours postoperatively | 48 hours postoperatively | 72 hours postoperatively | |
Bupivacaine Hydrochloride | 36.5 | 19 | 17 |
Exparel Injectable Product | 30 | 15 | 16 |
All narcotics administered in the first 0-8, 8-24, 24-48, and 48-72 hours and the total narcotics administered in the 0-72 hours postoperative period(PCA narcotics, nurse-administered IV narcotics, and oral narcotics). All narcotics will be converted to total IV morphine equivalent for comparison between two groups. (NCT03270514)
Timeframe: 0-72 hours post-operative period
Intervention | oral morphine equivalents in mg (Median) | ||||
---|---|---|---|---|---|
0-8 hours | 8-24 hours | 24-48 hours | 48-72 hours | 0-72 hours | |
Bupivacaine Hydrochloride | 10 | 34.5 | 45 | 26.5 | 105 |
Exparel Injectable Product | 15 | 45 | 45 | 15 | 139 |
AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge. (NCT03303794)
Timeframe: Post-Operation Day 1
Intervention | score on scale (Mean) |
---|---|
Bupivicaine | 23 |
Bupivicaine + Exparel | 23 |
Monitor how much opioid patient consumes (NCT03303794)
Timeframe: During the first 48 hours after surgery
Intervention | milligram (Mean) |
---|---|
Bupivicaine | 90 |
Bupivicaine + Exparel | 76 |
Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain. (NCT03303794)
Timeframe: 48 hours postoperatively
Intervention | score on scale (Mean) |
---|---|
Bupivicaine | 4 |
Bupivicaine + Exparel | 4 |
"The AUC of the NRS-R pain intensity scores from time 0 through 24 hours~The subject was to rest for at least 5 minutes before responding to the following question, On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?" (NCT00890682)
Timeframe: 0-24 hours
Intervention | Units on a scale*hours (Geometric Mean) |
---|---|
SKY0402 | 124 |
Placebo | 146 |
Frequency of postoperative opioid related adverse effects within the first week of surgery will be recorded. This includes nausea, vomiting, pruritus, allergy, respiratory depression. (NCT03722927)
Timeframe: Postoperatively, 1 week
Intervention | Participants (Count of Participants) |
---|---|
Bupivacaine Group | 0 |
Liposomal Bupivacaine Group | 0 |
The length of stay for hospitalization after mastectomy and breast reconstruction will be recorded. (NCT03722927)
Timeframe: up to 47 Hours
Intervention | days (Mean) |
---|---|
Bupivacaine Group | 1 |
Liposomal Bupivacaine Group | 1 |
This will be measured by the number of doses within the first month postoperatively and recorded on pain medication daily diary kept by subject. (NCT03722927)
Timeframe: 1 Month
Intervention | Number of morphine doses (Number) |
---|---|
Bupivacaine Group | 0 |
Liposomal Bupivacaine Group | 20 |
Readmission rates to the hospital within 2 months after mastectomy and breast reconstruction will be recorded (NCT03722927)
Timeframe: Month 2
Intervention | Participants (Count of Participants) |
---|---|
Bupivacaine Group | 0 |
Liposomal Bupivacaine Group | 0 |
This will be measured every 12 hours for the first 48 hours postoperatively by the level of breast pain associated with arm movements while eating on a scale of 0-10 with higher scores denoting worse outcomes. (NCT03722927)
Timeframe: 48 hours
Intervention | score on a scale (Mean) |
---|---|
12 hours | |
Bupivacaine Group | 4 |
This will be measured every 12 hours for the first 48 hours postoperatively by the level of breast pain associated with arm movements while eating on a scale of 0-10 with higher scores denoting worse outcomes. (NCT03722927)
Timeframe: 48 hours
Intervention | score on a scale (Mean) | |||
---|---|---|---|---|
12 hours | 24 hours | 36 hours | 48 hours | |
Liposomal Bupivacaine Group | 3.5 | 4 | 3.5 | 2 |
Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 16 hours post-op
Intervention | score on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 3.1 |
Bupivacaine HCl | 3.97 |
numeric rating scale (0-10), mean and SD, where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 2 hours post-op
Intervention | units on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 2.53 |
Bupivacaine HCl | 2.74 |
Pain scale measured from 0-10, where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 4 hours post-op
Intervention | Score on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 3.87 |
Bupivacaine HCl | 3 |
Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 8 hours post-op
Intervention | Score on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 3.77 |
Bupivacaine HCl | 3.67 |
Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: Post-Operative Day 14
Intervention | score on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 1.64 |
Bupivacaine HCl | 2.07 |
Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 2 days post-op
Intervention | score on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 3.34 |
Bupivacaine HCl | 4.17 |
Pain scale, where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 3 days post-op
Intervention | score on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 2.79 |
Bupivacaine HCl | 4.07 |
Numerical Rating Scale (0-10) post-operative pain score on POD1, where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 24 hours
Intervention | units on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 4.17 |
Bupivacaine HCl | 4.97 |
at time of post-op visit The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes (NCT02352922)
Timeframe: Post-Operative Day 14
Intervention | score on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 1.74 |
Bupivacaine HCl | 1.65 |
The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes (NCT02352922)
Timeframe: Post-Operative Day 2
Intervention | score on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 4.09 |
Bupivacaine HCl | 4.31 |
The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes (NCT02352922)
Timeframe: Post-Operative Day 3
Intervention | score on a scale (Mean) |
---|---|
Liposomal Bupivacaine | 3.36 |
Bupivacaine HCl | 3.94 |
Total use of home opioids by pill count/ oral morphine equivalents (NCT02352922)
Timeframe: Post-Operative Day 14
Intervention | mg (oral morphine equivalents) (Mean) |
---|---|
Liposomal Bupivacaine | 360 |
Bupivacaine HCl | 443 |
Total use of home opioids by pill count/ oral morphine equivalents (NCT02352922)
Timeframe: 72 hrs post-op
Intervention | mg (oral morphine equivalents) (Mean) |
---|---|
Liposomal Bupivacaine | 320 |
Bupivacaine HCl | 344 |
Oral morphine equivalent of opioid use while in the hospital (NCT02352922)
Timeframe: 24 hours
Intervention | mg (oral morphine equivalents) (Mean) |
---|---|
Liposomal Bupivacaine | 216 |
Bupivacaine HCl | 266 |
(NCT02352922)
Timeframe: Post-Operative Day 14
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Gas distension/bloated | Constipation | Nausea | Headache | Sore throat/cough | Dizziness | |
Bupivacaine HCl | 9 | 2 | 6 | 7 | 3 | 3 |
Liposomal Bupivacaine | 5 | 5 | 4 | 2 | 1 | 1 |
12 trials available for bupivacaine and Hallux Valgus
Article | Year |
---|---|
[Preemptive local anesthetic infiltration in hallux valgus one-day surgery].
Topics: Acetaminophen; Ambulatory Surgical Procedures; Anesthesia, Local; Anesthetics, Local; Bupivacaine; H | 2015 |
A "new" automated bolus technique for continuous popliteal block: a prospective, randomized comparison with a continuous infusion technique.
Topics: Anesthetics, Local; Bupivacaine; Double-Blind Method; Female; Hallux Valgus; Humans; Infusion Pumps; | 2008 |
[Ultrasound-guided single dose injection of 0.5% levobupivacaine or 0.5% ropivacaine for a popliteal fossa nerve block in unilateral hallux valgus surgery].
Topics: Aged; Amides; Analgesics; Anesthetics, Local; Bupivacaine; Female; Hallux Valgus; Humans; Injections | 2010 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double- | 2011 |
[Comparison of the post-surgical analgesic effectiveness of tibial (at internal malleolus level) and common peroneal nerve block with infiltration of the surgical wound in Outpatient Surgery of the hallux valgus].
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Analgesics; Ankle; Bupivacaine; Electric St | 2012 |
[Comparison of 3 combinations of 0.5% levobupivacaine and 1% mepivacaine in popliteal sciatic block in hallux valgus outpatient surgery].
Topics: Aged; Ambulatory Surgical Procedures; Anesthetics, Combined; Anesthetics, Local; Bupivacaine; Double | 2012 |
Sciatic nerve block with lateral popliteal approach for hallux vagus correction. Comparison between 0.5% bupivacaine and 0.75% ropivacaine.
Topics: Adult; Aged; Amides; Anesthetics, Local; Bupivacaine; Double-Blind Method; Female; Hallux Valgus; Hu | 2004 |
Stimulating popliteal catheters for postoperative analgesia after hallux valgus repair.
Topics: Aged; Bupivacaine; Catheterization; Female; Hallux Valgus; Humans; Levobupivacaine; Male; Middle Age | 2006 |
Ropivacaine and levobupivacaine for bilateral selective ankle block in patients undergoing hallux valgus repair.
Topics: Amides; Anesthetics, Local; Bupivacaine; Double-Blind Method; Elective Surgical Procedures; Female; | 2008 |
A double-blinded, randomized comparison of either 0.5% levobupivacaine or 0.5% ropivacaine for sciatic nerve block.
Topics: Adult; Aged; Amides; Anesthetics, Local; Bupivacaine; Double-Blind Method; Female; Femoral Nerve; Ha | 2002 |
Clinical properties of levobupivacaine or racemic bupivacaine for sciatic nerve block.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Bupivacaine; Double-Blind Method; Female; Femoral Nerve | 2002 |
The control of pain after Keller's procedure--a controlled double blind prospective trial with local anaesthetic and placebo.
Topics: Anesthesia, Local; Arthroplasty; Bupivacaine; Clinical Trials as Topic; Double-Blind Method; Hallux | 1985 |
2 other studies available for bupivacaine and Hallux Valgus
Article | Year |
---|---|
Liposomal bupivacaine in forefoot surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Fem | 2015 |
Liposomal bupivacaine in hallux valgus surgery: a multimodal pain management adjunct.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Bupivacaine; Female; Hallux Valgus; Humans; Male | 2014 |